Author

No. of Cases

Diagnosis

Drug

Dose

Age (yrs)

Gender

Presentation

RVSP

Younis, 2003 [26]

1

IgA (k), MM

Thal

400 mg/d then reduced to 100 mg/d then to 50 mg/d

51

M

Peripheral edema

70 mmHg (back to 47 mmHg after 2 months of Thal discontinuation)

Hattori et al., 2005 [27]

1

IgA (k), MM

Thal

400 mg/d

57

F

Mild dyspnea on exertion

NA

Antonioli et al., 2005 [28]

1

IgG (k), MM

Thal

100 mg/d with increase to 200 mg/d

63

M

Dizziness, asthenia and breathlessness

90 mmHg (reduced to 60 mmHg after one month of Thal discontinuation)

Lafaras et al., 2008 [23]

4

IgG (λ), MM

IgG (k), MM

IgG (k), MM

IgG (λ), MM

Thal

200 mg/d

59

68

72

76

M

F

NA

NA

Echocardiogram

98 mmHg

54 mmHg

NA

NA

Villa et al., 2011 [29]

1

IgG (λ), MM

Thal

50 mg/d

79

F

Asthenia, palpitation and dyspnea on exertion

75 mmHg (reduced to 26 mmHg after one month of Thal discontinuation)

Tamura et al., 2014 [30]

1

Primary plasma cell leukemia (PPCL)*

L

10 mg/d

76

M

Leg edema and dyspnea on exertion

Estimated mPAP 59 mmHg

Krishnan et al., 2015 [31]

2

IgA (k) MM

IgA (k) MM

(L&P)

Thal

NA

72

69

M

F

Worsening dyspnea on exertion

83 mmHg

65 mmHg